The Role of Additional Sex Combs-Like Proteins in Cancer.

Additional sex combs-like (ASXL) proteins are mammalian homologs of Addition of sex combs (Asx), a protein that regulates the balance of trithorax and Polycomb function in Drosophila. All three ASXL family members (ASXL1, ASXL2, and ASXL3) are affected by somatic or de novo germline mutations in cancer or rare developmental syndromes, respectively. Although Asx is characterized as a catalytic partner for the deubiquitinase Calypso (or BAP1), there are domains of ASXL proteins that are distinct from Asx and the roles and redundancies of ASXL members are not yet well understood. Moreover, it is not yet fully clarified if commonly encountered ASXL1 mutations result in a loss of protein or stable expression of a truncated protein with dominant-negative or gain-of-function properties. This review summarizes our current knowledge of the biological and functional roles of ASXL members in development, cancer, and transcription.

[1]  W. Hur,et al.  ASXL2 promotes proliferation of breast cancer cells by linking ERα to histone methylation , 2016, Oncogene.

[2]  O. Abdel-Wahab,et al.  Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.

[3]  Donna M. Martin,et al.  De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. , 2016, Human molecular genetics.

[4]  T. Sixma,et al.  BAP1/ASXL1 recruitment and activation for H2A deubiquitination , 2016, Nature Communications.

[5]  O. Abdel-Wahab,et al.  Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21) , 2016, Leukemia & lymphoma.

[6]  O. Abdel-Wahab,et al.  ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis , 2015 .

[7]  V. Jobanputra,et al.  Bohring–Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome , 2015, American journal of medical genetics. Part A.

[8]  A. Verma,et al.  ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts , 2015, Oncotarget.

[9]  S. Um,et al.  Role of Asxl1 in kidney podocyte development via its interaction with Wtip. , 2015, Biochemical and biophysical research communications.

[10]  O. Winther,et al.  Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals , 2015, Cell Research.

[11]  Frédérick A. Mallette,et al.  The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer*♦ , 2015, The Journal of Biological Chemistry.

[12]  L. Biesecker,et al.  Clinical management of patients with ASXL1 mutations and Bohring–Opitz syndrome, emphasizing the need for Wilms tumor surveillance , 2015, American journal of medical genetics. Part A.

[13]  S. Armstrong,et al.  Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.

[14]  A. Tefferi,et al.  ASXL1 mutations are frequent and prognostically detrimental in CSF3R‐mutated chronic neutrophilic leukemia , 2015, American journal of hematology.

[15]  H. Lähdesmäki,et al.  Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex , 2015, Nature Communications.

[16]  Matthew J. Silva,et al.  ASXL2 Regulates Glucose, Lipid, and Skeletal Homeostasis. , 2015, Cell reports.

[17]  M. Katoh.  Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine , 2015, Expert review of proteomics.

[18]  M. Oyama,et al.  The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitination , 2015, Leukemia.

[19]  D. Birnbaum,et al.  Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes , 2015, Oncotarget.

[20]  C. Preudhomme,et al.  Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors , 2015, Expert review of hematology.

[21]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[22]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[23]  O. Abdel-Wahab,et al.  Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. , 2014, Blood.

[24]  Q. T. Wang,et al.  Additional sex combs‐like family genes are required for normal cardiovascular development , 2014, Genesis.

[25]  Heather L. Mulder,et al.  The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.

[26]  S. Holland,et al.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation , 2014, Haematologica.

[27]  O. Abdel-Wahab,et al.  Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations , 2014, Haematologica.

[28]  Zhaomin Li,et al.  Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. , 2014, Blood.

[29]  P. Dubreuil,et al.  ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases , 2014, PloS one.

[30]  C. Mason,et al.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo , 2013, The Journal of experimental medicine.

[31]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[32]  H. Aburatani,et al.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. , 2013, The Journal of clinical investigation.

[33]  Laurie D. Smith,et al.  De novo frameshift mutation in ASXL3 in a patient with global developmental delay, microcephaly, and craniofacial anomalies , 2013, BMC Medical Genomics.

[34]  Q. T. Wang,et al.  Additional Sex Combs-Like 2 Is Required for Polycomb Repressive Complex 2 Binding at Select Targets , 2013, PloS one.

[35]  D. Birnbaum,et al.  Concomitant germ‐line RUNX1 and acquired ASXL1 mutations in a T‐cell acute lymphoblastic leukemia , 2013, European journal of haematology.

[36]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Faivre,et al.  Delineation of a new chromosome 20q11.2 duplication syndrome including the ASXL1 gene , 2013, American journal of medical genetics. Part A.

[38]  M. Katoh.  Functional and cancer genomics of ASXL family members , 2013, British Journal of Cancer.

[39]  J. Graham,et al.  Expanding our knowledge of conditions associated with the ASXL gene family , 2013, Genome Medicine.

[40]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[41]  J. Lupski,et al.  De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome , 2013, Genome Medicine.

[42]  Shamim A. K. Chowdhury,et al.  Maintenance of adult cardiac function requires the chromatin factor Asxl2. , 2012, Journal of molecular and cellular cardiology.

[43]  Somasekar Seshagiri,et al.  Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.

[44]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[45]  F. Prósper,et al.  Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics , 2012, PloS one.

[46]  Chris P. Ponting,et al.  A common ancestry for BAP1 and Uch37 regulators , 2012, Bioinform..

[47]  Bob Löwenberg,et al.  Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. , 2012, Blood.

[48]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[49]  G. Scarano,et al.  Two novel patients with Bohring–Opitz syndrome caused by de novo ASXL1 mutations , 2012, American journal of medical genetics. Part A.

[50]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[51]  L. Aravind,et al.  The HARE-HTH and associated domains , 2012, Cell cycle.

[52]  M. Caligiuri,et al.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. , 2011, Blood.

[53]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[54]  Huanming Yang,et al.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.

[55]  M. McDevitt,et al.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes , 2011, Haematologica.

[56]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[57]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[58]  L. Vissers,et al.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome , 2011, Nature Genetics.

[59]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[60]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[61]  C. Schumann,et al.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Eleazar Eskin,et al.  Mouse Genome-Wide Association and Systems Genetics Identify Asxl2 As a Regulator of Bone Mineral Density and Osteoclastogenesis , 2011, PLoS genetics.

[63]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[64]  S. Yoon,et al.  Additional Sex Comb-like (ASXL) Proteins 1 and 2 Play Opposite Roles in Adipogenesis via Reciprocal Regulation of Peroxisome Proliferator-activated Receptor γ* , 2010, The Journal of Biological Chemistry.

[65]  M. Wilm,et al.  Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB , 2010, Nature.

[66]  J. Hess,et al.  Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. , 2010, Blood.

[67]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[68]  Q. T. Wang,et al.  Functional Conservation of Asxl2, a Murine Homolog for the Drosophila Enhancer of Trithorax and Polycomb Group Gene Asx , 2009, PloS one.

[69]  Jürg Müller,et al.  A Genetic Screen Identifies Novel Polycomb Group Genes in Drosophila , 2007, Genetics.

[70]  R. Humphries,et al.  Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family. , 2006, Gene.

[71]  M. Katoh,et al.  Identification and characterization of ASXL2 gene in silico. , 2003, International journal of oncology.

[72]  H. Brock,et al.  A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11. , 2003, Gene.

[73]  C. Vandenberg,et al.  Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains , 2002, The EMBO journal.

[74]  T. Milne,et al.  The Additional sex combs gene of Drosophila is required for activation and repression of homeotic loci, and interacts specifically with Polycomb and super sex combs , 1999, Molecular and General Genetics MGG.

[75]  M. Kyba,et al.  The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes. , 1998, Development.

[76]  Keith D Wilkinson,et al.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.

[77]  C. H. Bartlett,et al.  Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. , 2015, The New England journal of medicine.

[78]  J. Hess,et al.  Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. , 2010, Developmental biology.